Skip to main content
. 2023 Sep 14;13(11):2394–2411. doi: 10.1158/2159-8290.CD-23-0436

Figure 2.

Figure 2. Pathologic regressions at surgery; genomic profiles of ITT population and correlates with pathologic responses. A, The magnitude of pathologic response is shown by percent residual viable tumor cells in resected tumor and nodal samples for all patients with available data (total N = 75; durvalumab monotherapy arm: n = 24; durvalumab + oleclumab arm: n = 18; durvalumab + monalizumab arm: n = 18; durvalumab + danvatirsen arm: n = 15), and annotated with histologic subtype, tumor mutational burden (TMB; mutations/megabase), and history of smoking. PD-L1 status (≥1% positive; <1% negative) from baseline tumor biopsies was determined by IHC (SP263) for all evaluable patients (n = 33). Presence of activating EGFR mutations or ALK fusions was determined by whole-exome sequencing (n = 34). B, Residual viable tumor cells (RVT) from resected tumor and nodal samples are reported as 0% to 100%, and MPR (RVT ≤10%) for n = 60 patients (durvalumab monotherapy: n = 24, durvalumab + oleclumab: n = 18; durvalumab + monalizumab: n = 18). Best response by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) is reported for n = 58 patients. Somatic tumor alterations identified in EGFR, KRAS, STK11, KEAP1, TP53, ALK, and RET genes are reported from tumor tissue for n = 35 patients. For patients with evaluable circulating tumor DNA (ctDNA) samples at baseline, each patient is identified as having detected or no detected ctDNA at baseline. For patients with detectable ctDNA at baseline (total N = 20; durvalumab monotherapy: n = 6; durvalumab + oleclumab: n = 7; durvalumab + monalizumab: n = 7), molecular response is depicted at end-of-treatment (day 28, n = 14) and follow-up (day 105, n = 15) time points for all patients with evaluable ctDNA at those time points and represented as complete molecular response [100% reduction in variant allele frequency (VAF) from baseline, also referred to as complete clearance], partial molecular response (≥50% reduction in VAF from baseline), or no molecular response (<50% reduction in VAF from baseline). BESTRESP, best response; FU, follow-up; MR, molecular response; WT, wild-type.

Pathologic regressions at surgery; genomic profiles of ITT population and correlates with pathologic responses. A, The magnitude of pathologic response is shown by percent residual viable tumor cells in resected tumor and nodal samples for all patients with available data (total N = 75; durvalumab monotherapy arm: n = 24; durvalumab + oleclumab arm: n = 18; durvalumab + monalizumab arm: n = 18; durvalumab + danvatirsen arm: n = 15), and annotated with histologic subtype, tumor mutational burden (TMB; mutations/megabase), and history of smoking. PD-L1 status (≥1% positive; <1% negative) from baseline tumor biopsies was determined by IHC (SP263) for all evaluable patients (n = 33). Presence of activating EGFR mutations or ALK fusions was determined by whole-exome sequencing (n = 34). B, Residual viable tumor cells (RVT) from resected tumor and nodal samples are reported as 0% to 100%, and MPR (RVT ≤10%) for n = 60 patients (durvalumab monotherapy: n = 24, durvalumab + oleclumab: n = 18; durvalumab + monalizumab: n = 18). Best response by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) is reported for n = 58 patients. Somatic tumor alterations identified in EGFR, KRAS, STK11, KEAP1, TP53, ALK, and RET genes are reported from tumor tissue for n = 35 patients. For patients with evaluable circulating tumor DNA (ctDNA) samples at baseline, each patient is identified as having detected or no detected ctDNA at baseline. For patients with detectable ctDNA at baseline (total N = 20; durvalumab monotherapy: n = 6; durvalumab + oleclumab: n = 7; durvalumab + monalizumab: n = 7), molecular response is depicted at end-of-treatment (day 28, n = 14) and follow-up (day 105, n = 15) time points for all patients with evaluable ctDNA at those time points and represented as complete molecular response [100% reduction in variant allele frequency (VAF) from baseline, also referred to as complete clearance], partial molecular response (≥50% reduction in VAF from baseline), or no molecular response (<50% reduction in VAF from baseline). BESTRESP, best response; FU, follow-up; MR, molecular response; WT, wild-type.